Literature DB >> 28126302

Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography.

William P Parker1, Jaden D Evans2, Bradley J Stish2, Sean S Park2, Kenneth Olivier2, Richard Choo2, Mark A Nathan3, Brian T Welch3, R Jeffrey Karnes1, Lance A Mynderse1, Thomas M Pisansky2, Eugene D Kwon1, Val J Lowe3, Brian J Davis4.   

Abstract

PURPOSE: To evaluate C-11 choline positron emission tomography/computed tomography (CholPET) in staging and determining patterns of recurrence in prostate cancer patients with rising prostate-specific antigen levels after prostatectomy radiation therapy (RT). METHODS AND MATERIALS: The study includes patients with biochemical failure after postprostatectomy RT who underwent CholPET between 2008 and 2015. Patient and disease characteristics were examined in relation to sites of recurrence. All RT dosimetry records were reviewed, and recurrences were mapped on a representative computed tomography dataset with their relationship relative to the irradiated fossa field as out of field (OOF), edge of field (EOF; recurrence within <45-Gy isodose lines), or in field (IF; recurrence within ≥45-Gy isodose lines).
RESULTS: Forty-one patients were identified with 121 sites of recurrence (median 2 sites; interquartile range [IQR], 1-4). The median prostate-specific antigen level at CholPET was 3.1 (IQR, 1.9-5.6) ng/mL. Median interval from RT to biochemical failure was 24 (IQR, 10-46) months, with recurrence identified on CholPET at a median of 15 (IQR, 7-28) months from biochemical failure. Histologic confirmation of recurrence was obtained in 20 patients (49%), with the remainder confirmed by treatment response. Five patients (12%) had IF recurrences, 10 patients (24%) had EOF recurrences (median dose 10 Gy; IQR, 5-30 Gy), and 36 patients (88%) had OOF recurrences. Ten patients had combination failures: 6 (15%) EOF/OOF and 4 (10%) IF/OOF. Fifty-seven recurrences (47%) were pelvic nodal sites inferior to the L5-S1 interspace, of which 52 (43%) were within a pelvic RT field. Eighty-one recurrences (67%) were nodal and inferior to the aortic bifurcation.
CONCLUSIONS: Using CholPET, we found that the majority of patients evaluated for biochemical failure recurred outside of the postprostatectomy RT field. Furthermore, most recurrence sites were nodal and inferior to the aortic bifurcation. These results provide data that may be useful for examining strategies that include elective lymph node irradiation in postprostatectomy patients.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28126302      PMCID: PMC5308881          DOI: 10.1016/j.ijrobp.2016.11.014

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  43 in total

1.  Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.

Authors:  Thomas Wiegel; Detlef Bartkowiak; Dirk Bottke; Claudia Bronner; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Normann Willich; Axel Semjonow; Michael Stöckle; Christian Rübe; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Rainer Hofmann; Rita Engenhart-Cabillic; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller
Journal:  Eur Urol       Date:  2014-03-21       Impact factor: 20.096

2.  Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. Lin CC, Gray PJ, Jemal A, Efstathiou JA, Surveillance and Health Services Research Program, Intramural Research, American Cancer Society, Atlanta, GA (CCL, AJ); Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (PJG, JAE); e-mail: jefstathiou@partners.org. J Natl Cancer Inst. 2015 May 9;107(7). pii: djv119. [Print 2015 Jul]. doi: 10.1093/jnci/djv119.

Authors:  Eggener Scott
Journal:  Urol Oncol       Date:  2017-02-01       Impact factor: 3.498

3.  (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.

Authors:  Tiziano Graziani; Francesco Ceci; Paolo Castellucci; Giulia Polverari; Giacomo Maria Lima; Filippo Lodi; Alessio Giuseppe Morganti; Andrea Ardizzoni; Riccardo Schiavina; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-08       Impact factor: 9.236

Review 4.  Current perspectives in the use of molecular imaging to target surgical treatments for genitourinary cancers.

Authors:  Francesco Greco; Jeffrey A Cadeddu; Inderbir S Gill; Jihad H Kaouk; Mesut Remzi; R Houston Thompson; Fijs W B van Leeuwen; Henk G van der Poel; Paolo Fornara; Jens Rassweiler
Journal:  Eur Urol       Date:  2013-08-07       Impact factor: 20.096

5.  Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease.

Authors:  William P Parker; Brian J Davis; Sean S Park; Kenneth R Olivier; Richard Choo; Mark A Nathan; Val J Lowe; Timothy J Welch; Jaden D Evans; William S Harmsen; Harras B Zaid; Ilya Sobol; Daniel M Moreira; Rimki Haloi; Matthew K Tollefson; Matthew T Gettman; Stephen A Boorjian; Lance A Mynderse; R Jeffrey Karnes; Eugene D Kwon
Journal:  Eur Urol       Date:  2016-09-03       Impact factor: 20.096

6.  Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer.

Authors:  Zachary S Zumsteg; Daniel E Spratt; Paul B Romesser; Xin Pei; Zhigang Zhang; Marisa Kollmeier; Sean McBride; Yoshiya Yamada; Michael J Zelefsky
Journal:  J Urol       Date:  2015-07-10       Impact factor: 7.450

7.  Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.

Authors:  Jeff M Michalski; Colleen Lawton; Issam El Naqa; Mark Ritter; Elizabeth O'Meara; Michael J Seider; W Robert Lee; Seth A Rosenthal; Thomas Pisansky; Charles Catton; Richard K Valicenti; Anthony L Zietman; Walter R Bosch; Howard Sandler; Mark K Buyyounouski; Cynthia Ménard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-23       Impact factor: 7.038

8.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

Authors:  Andrew J Stephenson; Peter T Scardino; Michael W Kattan; Thomas M Pisansky; Kevin M Slawin; Eric A Klein; Mitchell S Anscher; Jeff M Michalski; Howard M Sandler; Daniel W Lin; Jeffrey D Forman; Michael J Zelefsky; Larry L Kestin; Claus G Roehrborn; Charles N Catton; Theodore L DeWeese; Stanley L Liauw; Richard K Valicenti; Deborah A Kuban; Alan Pollack
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

9.  Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes.

Authors:  Piyush K Agarwal; Natalia Sadetsky; Badrinath R Konety; Martin I Resnick; Peter R Carroll
Journal:  Cancer       Date:  2008-01-15       Impact factor: 6.860

10.  Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.

Authors:  Nazareno Suardi; Giorgio Gandaglia; Andrea Gallina; Ettore Di Trapani; Vincenzo Scattoni; Damiano Vizziello; Vito Cucchiara; Roberto Bertini; Renzo Colombo; Maria Picchio; Giampiero Giovacchini; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2014-02-18       Impact factor: 20.096

View more
  10 in total

Review 1.  Analysis of FDA-approved imaging agents.

Authors:  Michael S Kinch; Pamela K Woodard
Journal:  Drug Discov Today       Date:  2017-03-21       Impact factor: 7.851

Review 2.  Patterns of Lymph Node Failure in Patients With Recurrent Prostate Cancer Postradical Prostatectomy and Implications for Salvage Therapies.

Authors:  Finbar Slevin; Matthew Beasley; William Cross; Andrew Scarsbrook; Louise Murray; Ann Henry
Journal:  Adv Radiat Oncol       Date:  2020-08-31

3.  Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT.

Authors:  Jaden D Evans; Lindsay K Morris; Henan Zhang; Siyu Cao; Xin Liu; Kristin C Mara; Bradley J Stish; Brian J Davis; Aaron S Mansfield; Roxana S Dronca; Matthew J Iott; Eugene D Kwon; Robert L Foote; Kenneth R Olivier; Haidong Dong; Sean S Park
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-09-08       Impact factor: 7.038

Review 4.  Contemporary role of postoperative radiotherapy for prostate cancer.

Authors:  Alan Dal Pra; Matthew C Abramowitz; Radka Stoyanova; Alan Pollack
Journal:  Transl Androl Urol       Date:  2018-06

5.  Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis.

Authors:  Changhoon Song; Sang Jun Byun; Young Seok Kim; Hanjong Ahn; Seok-Soo Byun; Choung-Soo Kim; Sang Eun Lee; Jae-Sung Kim
Journal:  PLoS One       Date:  2019-04-11       Impact factor: 3.240

6.  Mapping of Recurrence Sites Following Adjuvant or Salvage Radiotherapy for Prostate Cancer Patients.

Authors:  Ana Gonzalez-Moya; Stéphane Supiot; Valérie Seegers; Thibaut Lizée; Florence Legouté; Tanguy Perennec; Gilles Calais
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

7.  Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications.

Authors:  Brian T Welch; Ann T Packard; Thomas D Atwell; Geoffrey B Johnson; Val J Lowe; Robert Jeffrey Karnes; Lance A Mynderse; Tina M Gunderson; Sean S Park; Bradley J Stish; Jaden D Evans; Eugene D Kwon; Brian J Davis; Mark A Nathan
Journal:  Adv Radiat Oncol       Date:  2018-09-05

8.  11C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities.

Authors:  Krishan R Jethwa; Christopher D Hellekson; Jaden D Evans; William S Harmsen; Tyler J Wilhite; Thomas J Whitaker; Sean S Park; C Richard Choo; Bradley J Stish; Kenneth R Olivier; Rimki Haloi; Val J Lowe; Brian T Welch; J Fernando Quevedo; Lance A Mynderse; R Jeffrey Karnes; Eugene D Kwon; Brian J Davis
Journal:  Adv Radiat Oncol       Date:  2019-07-04

9.  Pattern of failure in prostate cancer previously treated with radical prostatectomy and post-operative radiotherapy: a secondary analysis of two prospective studies using novel molecular imaging techniques.

Authors:  Lindsay S Rowe; Stephanie Harmon; Adam Horn; Uma Shankavaram; Soumyajit Roy; Holly Ning; Liza Lindenberg; Esther Mena; Deborah E Citrin; Peter Choyke; Baris Turkbey
Journal:  Radiat Oncol       Date:  2021-02-10       Impact factor: 3.481

10.  Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA-GEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP.

Authors:  Stéphane Supiot; Loic Campion; Pascal Pommier; Mélanie Dore; Clément Palpacuer; Séverine Racadot; Emmanuel Rio; Gérard A Milano; Céline Mahier-Ait Oukhatar; Christian Carrie
Journal:  Oncotarget       Date:  2018-04-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.